MORROW GEORGE J 4

What Happened
George J. Morrow, a director of Neurocrine Biosciences, was granted 2,567 Restricted Stock Units (RSUs) on May 27, 2026. The award is reported as a derivative grant at $0.00 per RSU (no cash paid at grant). Each RSU represents the right to receive one share of common stock upon vesting.

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 29, 2026 (filed within the standard two-business-day reporting window).
• Transaction type/code: Award/Grant (A) of RSUs (derivative).
• Shares/units granted: 2,567 RSUs; grant price reported $0.00; reported value at grant = $0 (derivative award).
• Vesting: RSUs vest in full on May 27, 2027 (per filing footnote).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Notable footnotes: F1 explains each RSU converts to one share on vesting; F2 specifies full vest date.

Context
RSU grants are common executive/director compensation and do not involve an immediate purchase or sale of shares. They generally do not indicate near-term buying or selling intent — value is realized only if/when RSUs vest (and may be subject to tax withholding). For retail investors, purchases by insiders are often more directly informative of personal conviction; awards are routine compensation tied to service or retention.